Sage Therapeutics Company Profile (NASDAQ:SAGE)

About Sage Therapeutics

Sage Therapeutics logoSAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. Its lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the GABAA receptor. Its product candidates, SAGE-217 and SAGE-689, also targets the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors. Its SAGE-718 is a product candidate selected for development from its NMDA receptor program.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: SAGE
  • CUSIP:
Key Metrics:
  • Previous Close: $64.98
  • 50 Day Moving Average: $51.75
  • 200 Day Moving Average: $46.28
  • 52-Week Range: $26.28 - $66.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -12.47
  • P/E Growth: 0.00
  • Market Cap: $2.42B
  • Outstanding Shares: 37,167,000
  • Beta: 2.73
Profitability:
  • Return on Equity: -46.51%
  • Return on Assets: -43.72%
Debt:
  • Current Ratio: 19.47%
  • Quick Ratio: 19.47%
Additional Links:
Companies Related to Sage Therapeutics:

Analyst Ratings

Consensus Ratings for Sage Therapeutics (NASDAQ:SAGE) (?)
Ratings Breakdown: 1 Hold Rating, 10 Buy Ratings, 1 Strong Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $77.75 (19.65% upside)

Analysts' Ratings History for Sage Therapeutics (NASDAQ:SAGE)
Show:
DateFirmActionRatingPrice TargetDetails
2/14/2017Chardan CapitalUpgradeSell -> Neutral$60.00View Rating Details
2/13/2017Cowen and CompanyReiterated RatingBuy$95.00View Rating Details
2/13/2017BMO Capital MarketsSet Price TargetOutperform -> Buy$68.00View Rating Details
1/11/2017J P Morgan Chase & CoReiterated RatingBuyView Rating Details
12/14/2016Canaccord GenuitySet Price TargetBuy$110.00View Rating Details
12/14/2016Raymond James Financial, Inc.UpgradeOutperform -> Strong-Buy$84.00View Rating Details
11/14/2016Stifel NicolausInitiated CoverageBuy$90.00View Rating Details
10/4/2016Leerink SwannReiterated RatingOutperform$68.00View Rating Details
7/15/2016William BlairReiterated RatingOutperform$75.00View Rating Details
6/23/2016HC WainwrightInitiated CoverageBuy$56.00View Rating Details
4/1/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$63.00View Rating Details
3/11/2016Lake Street CapitalInitiated CoverageBuy$90.00View Rating Details
(Data available from 2/20/2015 forward)

Earnings

Earnings History for Sage Therapeutics (NASDAQ:SAGE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017($1.17)N/AView Earnings Details
11/3/2016Q316($1.10)($1.15)ViewN/AView Earnings Details
8/9/2016Q216($1.02)($1.08)ViewN/AView Earnings Details
5/5/2016Q1($0.98)($0.97)ViewListenView Earnings Details
2/24/2016Q4($0.94)($0.99)ViewListenView Earnings Details
8/12/2015Q215($0.68)($0.90)ViewN/AView Earnings Details
5/14/2015Q115($0.56)($0.66)ViewN/AView Earnings Details
2/27/2015Q414($0.44)($1.57)ViewN/AView Earnings Details
11/11/2014Q314($0.40)($0.50)ViewN/AView Earnings Details
8/14/2014Q214($1.23)($4.57)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sage Therapeutics (NASDAQ:SAGE)
Current Year EPS Consensus Estimate: $-4.37 EPS
Next Year EPS Consensus Estimate: $-5.21 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.99)($0.91)($0.95)
Q2 20164($1.12)($0.94)($1.03)
Q3 20164($1.16)($1.07)($1.12)
Q4 20164($1.17)($1.12)($1.13)
Q1 20171($1.20)($1.20)($1.20)
Q2 20171($1.31)($1.31)($1.31)
Q3 20171($1.43)($1.43)($1.43)
Q4 20171($1.53)($1.53)($1.53)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Sage Therapeutics (NASDAQ:SAGE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sage Therapeutics (NASDAQ:SAGE)
Insider Ownership Percentage: 5.60%
Institutional Ownership Percentage: 99.92%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/13/2017Kimi IguchiCFOSell10,000$53.92$539,200.00View SEC Filing  
11/17/2016Kimi IguchiCFOSell4,000$51.77$207,080.00View SEC Filing  
11/11/2016Kimi IguchiCFOSell1,500$50.59$75,885.00View SEC Filing  
9/7/2016Kimi IguchiCFOSell2,500$40.93$102,325.00View SEC Filing  
7/12/2016Albert RobichaudInsiderSell22,000$40.00$880,000.00View SEC Filing  
7/12/2016Kimi IguchiCFOSell5,000$49.55$247,750.00View SEC Filing  
5/16/2016Kevin P StarrDirectorSell850,000$31.25$26,562,500.00View SEC Filing  
4/19/2016Stephen KanesInsiderSell21,000$38.00$798,000.00View SEC Filing  
1/25/2016Albert RobichaudInsiderSell20,000$40.02$800,400.00View SEC Filing  
9/28/2015Stephen KanesinsiderSell6,000$46.42$278,520.00View SEC Filing  
9/8/2015Kimi IguchiCFOSell3,000$54.84$164,520.00View SEC Filing  
9/1/2015Steven M. PaulDirectorSell20,000$52.41$1,048,200.00View SEC Filing  
8/31/2015Stephen KanesInsiderSell12,000$53.12$637,440.00View SEC Filing  
7/23/2015Jeffrey M JonasInsiderSell3,000$76.79$230,370.00View SEC Filing  
7/6/2015Kimi IguchiCFOSell4,000$68.00$272,000.00View SEC Filing  
7/1/2015Albert RobichaudInsiderSell16,000$72.13$1,154,080.00View SEC Filing  
7/1/2015Steven M PaulDirectorSell20,000$69.40$1,388,000.00View SEC Filing  
6/24/2015Stephen KanesInsiderSell6,000$74.06$444,360.00View SEC Filing  
6/16/2015Jeffrey M JonasInsiderSell198,600$77.36$15,363,696.00View SEC Filing  
6/8/2015Thomas AndersonInsiderSell5,500$79.65$438,075.00View SEC Filing  
6/1/2015Albert RobichaudInsiderSell16,000$72.80$1,164,800.00View SEC Filing  
6/1/2015Steven M PaulDirectorSell20,000$72.34$1,446,800.00View SEC Filing  
2/25/2015Stephen KanesInsiderSell6,000$42.05$252,300.00View SEC Filing  
1/26/2015Stephen KanesInsiderSell6,000$37.29$223,740.00View SEC Filing  
7/23/2014James M FratesDirectorBuy5,000$18.00$90,000.00View SEC Filing  
7/23/2014Stephen KanesInsiderBuy3,000$18.00$54,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Sage Therapeutics (NASDAQ:SAGE)
DateHeadline
us.rd.yahoo.com logo3:05 am SAGE Therapeutics issues statement that co is not in M&A discussions (NASDAQ:SAGE)
us.rd.yahoo.com - February 19 at 9:03 AM
wsj.com logo[$$] OVERHEARD: Talking Too Much? (NASDAQ:SAGE)
www.wsj.com - February 18 at 8:30 AM
News IconCan We Learn Anything From The Technical Chart of Sage Therapeutics, Inc. (SAGE)? - NY Stock News (NASDAQ:SAGE)
nystocknews.com - February 17 at 7:45 PM
News IconABR Of Sage Therapeutics, Inc. (NASDAQ:SAGE) Stock At 1.22 - Stock Observer (NASDAQ:SAGE)
www.thestockobserver.com - February 17 at 7:45 PM
News IconAverage Brokerage Rating Of Ciena Corporation (CIEN), Sage Therapeutics, Inc. (SAGE) - The USA Commerce (NASDAQ:SAGE)
www.theusacommerce.com - February 17 at 7:45 PM
businesswire.com logoSage Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, February 23, 2017 - Business Wire (press release) (NASDAQ:SAGE)
www.businesswire.com - February 17 at 7:45 PM
finance.yahoo.com logoSage Therapeutics to Report Fourth Quarter and Full Year 2016 Financial Results on Thursday, February 23, 2017 (NASDAQ:SAGE)
finance.yahoo.com - February 17 at 7:45 PM
thestreet.com logoSage Therapeutics Leads Biotech Movers on False Takeout Rumors (NASDAQ:SAGE)
www.thestreet.com - February 17 at 7:45 PM
finance.yahoo.com logoStress boom to boost drug sales? (NASDAQ:SAGE)
finance.yahoo.com - February 16 at 7:22 PM
finance.yahoo.com logoStress boom to boost drug sales? (NASDAQ:SAGE)
finance.yahoo.com - February 16 at 7:22 PM
rttnews.com logoSAGE Therapeutics Inc. (SAGE) Rose To A 3-Week High On Phase 2 Study News (NASDAQ:SAGE)
www.rttnews.com - February 15 at 2:07 AM
nasdaq.com logoSAGE Therapeutics Inc. (SAGE) Is Climbing On Phase 2 Study Results (NASDAQ:SAGE)
www.nasdaq.com - February 15 at 2:07 AM
insidermonkey.com logoPositive Results For MDD Drug Sends Shares Of SAGE Therapeutics Inc (SAGE) Soaring (NASDAQ:SAGE)
www.insidermonkey.com - February 15 at 2:07 AM
thestreet.com logoBiotech Premarket Movers: Sage Therapeutics, Immunomedics, Myriad Genetics (NASDAQ:SAGE)
us.rd.yahoo.com - February 15 at 2:06 AM
bizjournals.com logoSage Therapeutics gains $220M in value as depression drug clears trial hurdle (NASDAQ:SAGE)
us.rd.yahoo.com - February 15 at 2:06 AM
us.rd.yahoo.com logoCan Sage Therapeutics Press Even Further With Its Depression Trial? (NASDAQ:SAGE)
us.rd.yahoo.com - February 15 at 2:06 AM
us.rd.yahoo.com logoSage Therapeutics Surges: A Little Bit Of Data Goes A Long Way (NASDAQ:SAGE)
us.rd.yahoo.com - February 15 at 2:06 AM
thestreet.com logoSage Therapeutics Lifts Investor Spirits With Sliver of Depression Drug Data (NASDAQ:SAGE)
us.rd.yahoo.com - February 15 at 2:06 AM
finance.yahoo.com logoSAGE Therapeutics upgraded by Chardan Capital Markets (NASDAQ:SAGE)
finance.yahoo.com - February 15 at 2:06 AM
News IconSAGE-217, The Postpartum Depression From SAGE Therapeutics Inc (NASDAQ:SAGE) Is Safe And Tolerable - FinancialsTrend (NASDAQ:SAGE)
www.financialstrend.com - February 14 at 6:10 AM
blogs.barrons.com logoSage Therapeutics Surges: A Little Bit Of Data Goes A Long Way ... - Barron's (blog) (NASDAQ:SAGE)
blogs.barrons.com - February 14 at 6:10 AM
finance.yahoo.com logoCan Sage Therapeutics Press Even Further With Its Depression Trial? - Yahoo Finance (NASDAQ:SAGE)
finance.yahoo.com - February 14 at 6:10 AM
fool.com logoWhy Sage Therapeutics Jumped Today - Motley Fool (NASDAQ:SAGE)
www.fool.com - February 14 at 6:10 AM
cnbc.com logoSage Therapeutics shares jump after depression drug trial results (NASDAQ:SAGE)
www.cnbc.com - February 14 at 6:10 AM
streetinsider.com logoSAGE Therapeutics (SAGE) Reports Top-Line Results from Phase 2 ... - StreetInsider.com (NASDAQ:SAGE)
www.streetinsider.com - February 13 at 8:34 AM
finance.yahoo.com logoSage Therapeutics Advances SAGE-217 into Placebo-Controlled Phase 2 Clinical Trial in Major Depressive Disorder (NASDAQ:SAGE)
finance.yahoo.com - February 13 at 8:34 AM
finance.yahoo.com logo7:04 am SAGE Therapeutics announces 'encouraging' top-line results from its Phase 2 clinical trial of orally-administered SAGE-217 for the treatment of major depressive disorder; study 'demonstrates positive signal of activity and tolerabil (NASDAQ:SAGE)
finance.yahoo.com - February 13 at 8:34 AM
streetinsider.com logoForm 4 Sage Therapeutics, Inc. For: Feb 06 Filed by: Anderson Thomas - StreetInsider.com (NASDAQ:SAGE)
www.streetinsider.com - February 10 at 11:37 PM
News IconNotable Thursday Option Activity: AQMS, SAGE, CIEN (NASDAQ:SAGE)
www.stockoptionschannel.com - February 10 at 1:34 AM
finance.yahoo.com logoSage Therapeutics to Participate in Upcoming February Investor Conferences (NASDAQ:SAGE)
finance.yahoo.com - February 8 at 1:16 AM
News IconSage Therapeutics Inc SAGE Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:SAGE)
www.bioportfolio.com - February 2 at 12:36 AM
News IconSage Therapeutics INC (SAGE) Holder Oak Ridge Investments LLC Has Raised Its Position as Share Value Rose (NASDAQ:SAGE)
randolphguide.com - February 2 at 12:36 AM
News IconIs SAGE Therapeutics Inc (SAGE)’s Fuel Running High? The Stock Formed Bullish Multiple Top (NASDAQ:SAGE)
randolphguide.com - January 31 at 2:25 AM
News IconIs SAGE Therapeutics Inc (SAGE)'s Fuel Running High? The Stock Formed Bullish Multiple Top - The Randolph Guide (NASDAQ:SAGE)
randolphguide.com - January 30 at 8:57 PM
News IconValue Composite Score Update on Sage Therapeutics, Inc. (NASDAQ:SAGE) - The Tribune (NASDAQ:SAGE)
lakecitytribune.com - January 29 at 8:19 AM
News IconSage Therapeutics, Inc. (NASDAQ:SAGE) Stock ABR At 1.44 - Stock Observer (NASDAQ:SAGE)
www.thestockobserver.com - January 29 at 8:19 AM
News IconEarnings in Full Force, Analysts Take Aim at Sage Therapeutics, Inc. (NASDAQ:SAGE) - Wall Street Beacon (NASDAQ:SAGE)
wsbeacon.com - January 26 at 4:40 AM
News IconWhat are Analysts Expecting for Sage Therapeutics, Inc. (NASDAQ:SAGE) Earnings? - Aiken Advocate (NASDAQ:SAGE)
aikenadvocate.com - January 21 at 4:29 AM
News IconStock ABR Sage Therapeutics, Inc. (NASDAQ:SAGE) At 1.44 - Stock Observer (NASDAQ:SAGE)
www.thestockobserver.com - January 21 at 4:29 AM
News IconWill The Needle Move For Sage Therapeutics, Inc. (NASDAQ:SAGE ... - Wall Street Beacon (NASDAQ:SAGE)
wsbeacon.com - January 18 at 9:18 PM
News IconShooting From the Hip, Stock Reaches Most Volatile List: Sage Therapeutics, Inc. (NASDAQ:SAGE) - Wall Street Beacon (NASDAQ:SAGE)
wsbeacon.com - January 18 at 9:18 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Sage ... - Wall Street Beacon (NASDAQ:SAGE)
wsbeacon.com - January 15 at 8:28 AM
News IconStock ABR Sage Therapeutics, Inc. (NASDAQ:SAGE) At 1.44 | Stock ... - Stock Observer (NASDAQ:SAGE)
www.thestockobserver.com - January 14 at 7:42 PM
streetinsider.com logoForm 4 Sage Therapeutics, Inc. For: Jan 13 Filed by: IGUCHI KIMI - StreetInsider.com (NASDAQ:SAGE)
www.streetinsider.com - January 14 at 7:42 PM
News IconMarkets End Mostly Higher, How Did This Stock Fare: Sage Therapeutics, Inc. (NASDAQ:SAGE) - Wall Street Beacon (NASDAQ:SAGE)
wsbeacon.com - January 14 at 7:42 PM
News IconSage Therapeutics, Inc. (SAGE) stock slides, "Buy" rating reiterated by J P Morgan Chase & Co Analysts - BNB Daily (blog) (NASDAQ:SAGE)
www.baseball-news-blog.com - January 12 at 9:06 PM
News IconNotable Runner: Could SAGE Therapeutics Inc See a Reversal After This Very Strong Session? - Fair View Times (NASDAQ:SAGE)
fairviewtimes.com - January 12 at 9:06 PM
News IconHigh-Risk EEG Patterns in Critically Ill May Predict Seizures (NASDAQ:SAGE)
www.medscape.com - January 11 at 10:17 PM
News IconSage Therapeutics, Inc. - Product Pipeline Review - 2016 (NASDAQ:SAGE)
www.reportsnreports.com - January 9 at 9:09 PM
News IconStock ABR Of Sage Therapeutics, Inc. (NASDAQ:SAGE) At 1.44 - Stock Observer (NASDAQ:SAGE)
www.thestockobserver.com - January 6 at 9:12 PM

Social

What is Sage Therapeutics' stock symbol?

Sage Therapeutics trades on the NASDAQ under the ticker symbol "SAGE."

Where is Sage Therapeutics' stock going? Where will Sage Therapeutics' stock price be in 2017?

12 analysts have issued 12 month price objectives for Sage Therapeutics' stock. Their forecasts range from $56.00 to $110.00. On average, they anticipate Sage Therapeutics' stock price to reach $77.75 in the next twelve months.

When will Sage Therapeutics announce their earnings?

Sage Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February, 22nd 2017.

What are analysts saying about Sage Therapeutics stock?

Here are some recent quotes from research analysts about Sage Therapeutics stock:

  • Chardan Capital analysts commented, "Yesterday, Sage Therapeutics announced encouraging top-line phase II results from its open label clinical trial of orally-administered SAGE-217 for major depressive disorder (MDD). Our discussions yesterday with industry participants in the depression space suggested a decidedly positive view of the SAGE-217 data. We now note that the SAGE-217 result follows what to us, in our 12 July 2016 research, was "potentially clear, positive" phase II data for IV SAGE-547 in severe postpartum depression (PPD). Although our 20 July 2016 questions on SAGE-547 remain unanswered, we are reassured by the granting of Breakthrough Therapy Designation (BTD) for SAGE-547 by the FDA and PRIME Designation by EMA, which both likely independently considered the issues we raised. Our initial 24 May 2016 bearish view on Sage was based largely on our expectations of phase III data for SAGE-547 in super-refractory status epilepticus (SRSE), which were originally due to read out in 2H16. The timing of the data has since moved to 1H17, exposing any SAGE-547 SRSE bear thesis to the upside potential surrounding SAGE-217 in MDD, and more limited potential of SAGE-547 in PPD. Indeed, we now see upside risk elsewhere in Sage and thereby upgrade from Sell to Neutral, raising our PT from $18 to $60." (2/14/2017)
  • Cowen and Company analysts commented, "Today SAGE announced positive top-line results from its Ph2 OL trial of SAGE-217 in." (2/13/2017)

  • BMO Capital Markets analysts commented, "While still early, we believe the data are impressive and help validate the mechanism of SAGE-217 as a potent oral compound impacting the GABA pathway. We view the opportunity in MDD as significant optionality on the stock given the size of the market." (2/13/2017)
  • Canaccord Genuity analysts commented, "We are encouraged by NDRM’s progress on its multiple development programs and continue to view the company’s approach to treating Parkinson’s disease as potentially paradigm-shifting. NDRM recently had an end of Ph2 meeting with the FDA to discuss ND0612 and has been allowed to move forward with PK equivalency in the US as opposed to doing a Ph3 efficacy trial. Additionally, NDRM announced positive top-line data from a pilot PK trial of ND0701 last week." (12/6/2016)

  • According to Zacks Investment Research, "SAGE Therapeutics Inc. is a biopharmaceutical company developing and commercializing medicines to treat life-threatening central nervous system (CNS) disorders. The Company provides treatments for schizophrenia, major depressive disorder, pain, and traumatic brain injury conditions. Its initial product candidates include SAGE-547, SAGE-689 and SAGE-217. SAGE Therapeutics, Inc. is based in Cambridge, Massachusetts. " (8/26/2016)

Who owns Sage Therapeutics stock?

Sage Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), State Street Corp (3.11%), Franklin Resources Inc. (3.02%), Palo Alto Investors LLC (2.72%), Federated Investors Inc. PA (2.58%) and Marshall Wace LLP (0.83%). Company insiders that own Sage Therapeutics stock include Albert Robichaud, Jeffrey M Jonas, Kevin P Starr, Kimi Iguchi, Stephen Kanes, Steven M Paul and Thomas Anderson.

Who sold Sage Therapeutics stock? Who is selling Sage Therapeutics stock?

Sage Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Federated Investors Inc. PA, Frontier Capital Management Co. LLC, Clarius Group LLC, Franklin Resources Inc., Harbourvest Partners LLC, State Street Corp and Trexquant Investment LP. Company insiders that have sold Sage Therapeutics stock in the last year include Albert Robichaud, Kevin P Starr, Kimi Iguchi and Stephen Kanes.

Who bought Sage Therapeutics stock? Who is buying Sage Therapeutics stock?

Sage Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including New Leaf Venture Partners L.L.C., Palo Alto Investors LLC, FMR LLC, Guggenheim Capital LLC, Nicholas Investment Partners LP, Russell Investments Group Ltd., Arthur M. Cohen & Associates LLC and Oxford Asset Management.

How do I buy Sage Therapeutics stock?

Shares of Sage Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Sage Therapeutics stock cost?

One share of Sage Therapeutics stock can currently be purchased for approximately $64.98.

Sage Therapeutics (NASDAQ:SAGE) Chart for Monday, February, 20, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Earnings History Chart

Earnings by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Dividend History Chart

Dividend Payments by Quarter for Sage Therapeutics (NASDAQ:SAGE)

Last Updated on 2/20/2017 by MarketBeat.com Staff